An Open-label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second line Therapy in Patients With Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Diseases and Conditions Researched
Bladder; Kidney; Other Urinary
What is the purpose of this trial?
To evaluate the progression-free survival (PFS) in patients with metastatic transitional cell carcinoma (TCC) when treated with docetaxel monotherapy or docetaxel in combination with either the monoclonal antibody ramucirumab (IMC-1121B) drug product (hereafter referred to as ramucirumab DP) or IMC-18F1.
Click here for detailed participation information for this trial.
|Sponsor:||Imclone Systems, Inc.|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.